Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Verastem, Inc.
National Cancer Institute (NCI)
Sun Yat-sen University
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Boehringer Ingelheim
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Taiho Oncology, Inc.
NRG Oncology
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Boehringer Ingelheim
Gilead Sciences
Pfizer
AstraZeneca
Revolution Medicines, Inc.
AstraZeneca
Hoffmann-La Roche
Shanghai Chest Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Massachusetts General Hospital
University Medical Center Groningen
Regeneron Pharmaceuticals
Big Ten Cancer Research Consortium
Inhibrx Biosciences, Inc
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
National Cancer Institute (NCI)
Lantern Pharma Inc.
University of Kentucky
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Guangzhou JOYO Pharma Co., Ltd
BeiGene
Masonic Cancer Center, University of Minnesota
University Hospital, Essen